These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 31264312

  • 1. Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease.
    Sun PP, Yu XJ, Wang SX, Zhou XJ, Qu L, Zhang F, Ma YY, Liu G, Yang L.
    Nephrology (Carlton); 2020 Feb; 25(2):125-134. PubMed ID: 31264312
    [Abstract] [Full Text] [Related]

  • 2. A rare case of renal thrombotic microangiopathy associated with Castleman's disease.
    Mutneja A, Cossey LN, Liapis H, Chen YM.
    BMC Nephrol; 2017 Feb 10; 18(1):57. PubMed ID: 28183278
    [Abstract] [Full Text] [Related]

  • 3. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
    Nishi J, Maruyama I.
    Leuk Lymphoma; 2000 Jul 10; 38(3-4):387-94. PubMed ID: 10830746
    [Abstract] [Full Text] [Related]

  • 4. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
    Nagayama Y, Yamano M, Yagame M, Nariyama T, Takahashi M, Kawamoto M, Matsui K.
    BMC Nephrol; 2019 Oct 17; 20(1):375. PubMed ID: 31623576
    [Abstract] [Full Text] [Related]

  • 5. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
    Leurs A, Gnemmi V, Lionet A, Renaud L, Gibier JB, Copin MC, Hachulla E, Hatron PY, Launay D, Fajgenbaum D, Terriou L.
    Front Immunol; 2019 Oct 17; 10():1489. PubMed ID: 31316523
    [Abstract] [Full Text] [Related]

  • 6. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.
    Lajoie G, Kumar S, Min KW, Silva FG.
    Am J Surg Pathol; 1995 Sep 17; 19(9):1021-8. PubMed ID: 7661275
    [Abstract] [Full Text] [Related]

  • 7. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?
    Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, Okino T, Ichimura K, Yoshino T, Makino H.
    Am J Kidney Dis; 2004 Jan 17; 43(1):E3-9. PubMed ID: 14712466
    [Abstract] [Full Text] [Related]

  • 8. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
    Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, Ijichi O, Ikarimoto N, Nakata M, Kitajima I, Fukushige T, Takamatsu H, Miyata K, Maruyama I.
    Br J Haematol; 1999 Mar 17; 104(3):482-5. PubMed ID: 10086783
    [Abstract] [Full Text] [Related]

  • 9. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
    Lee JP, Kim DK, Oh DY, Paik JH, Moon KC, Kim S, Kim YS.
    Clin Nephrol; 2011 Feb 17; 75(2):165-70. PubMed ID: 21255547
    [Abstract] [Full Text] [Related]

  • 10. Thrombotic microangiopathy in patients with diabetic nephropathy is associated with low VEGF expression and end-stage renal disease
.
    Hernández-Arteaga K, Soto-Abraham V, Pérez-Navarro M, de León-Garza B, Rodríguez-Matías A, Olvera-Soto MG, Valdez-Ortiz R.
    Clin Nephrol; 2018 Jun 17; 89(6):429-437. PubMed ID: 29249229
    [Abstract] [Full Text] [Related]

  • 11. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
    Ozawa M, Ohtani H, Komatsuda A, Wakui H, Takahashi N.
    Clin Exp Nephrol; 2021 Nov 17; 25(11):1193-1202. PubMed ID: 34115234
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV.
    Hum Pathol; 2014 Sep 17; 45(9):1918-27. PubMed ID: 25087655
    [Abstract] [Full Text] [Related]

  • 13. Podocyte Involvement in Renal Thrombotic Microangiopathy: A Clinicopathological Study.
    Hu YF, Tan Y, Yu XJ, Wang H, Wang SX, Yu F, Zhao MH.
    Am J Nephrol; 2020 Sep 17; 51(9):752-760. PubMed ID: 32862175
    [Abstract] [Full Text] [Related]

  • 14. A Case of the nephrotic syndrome in bone marrow transplantation recipient, histologically showing overlapped glomerular lesions of thrombotic microangiopathy and membranous nephropathy.
    Masuzawa N, Nishimura A, Kitani T, Tamagaki K, Sugitani M, Nagoshi H, Kuroda J, Konishi E.
    Pathol Int; 2017 Dec 17; 67(12):620-625. PubMed ID: 28940837
    [Abstract] [Full Text] [Related]

  • 15. ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.
    Erpenbeck L, Demers M, Zsengellér ZK, Gallant M, Cifuni SM, Stillman IE, Karumanchi SA, Wagner DD.
    J Am Soc Nephrol; 2016 Jan 17; 27(1):120-31. PubMed ID: 26038528
    [Abstract] [Full Text] [Related]

  • 16. TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.
    Tu KH, Fan PY, Chen TD, Chuang WY, Wu CY, Ku CL, Tian YC, Yang CW, Fang JT, Yang HY.
    Int J Mol Sci; 2021 Jun 11; 22(12):. PubMed ID: 34208103
    [Abstract] [Full Text] [Related]

  • 17. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
    Pfister F, Amann K, Daniel C, Klewer M, Büttner A, Büttner-Herold M.
    Histopathology; 2018 Dec 11; 73(6):990-1001. PubMed ID: 30014486
    [Abstract] [Full Text] [Related]

  • 18. Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.
    Saito H, Tanaka K, Fujiwara M, Iwasaki T, Numata T, Oda A, Kanno M, Tanaka M, Eiro M, Satoh M, Kazama JJ.
    CEN Case Rep; 2019 Nov 11; 8(4):239-245. PubMed ID: 31077056
    [Abstract] [Full Text] [Related]

  • 19. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.
    Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, Baumelou A, Derosa L, Bahleda R, Hollebecque A, Sahali D, Soria JC.
    Medicine (Baltimore); 2014 Nov 11; 93(24):333-339. PubMed ID: 25500702
    [Abstract] [Full Text] [Related]

  • 20. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
    Yamada R, Okawa T, Matsuo K, Suzuki M, Mori N, Mori K.
    BMC Nephrol; 2019 Jan 11; 20(1):14. PubMed ID: 30634936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.